Wells Fargo & Company Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price dropped by equities research analysts at Wells Fargo & Company from $800.00 to $700.00 in a report issued on Monday,Benzinga reports. The firm currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 12.49% from the stock’s current price.

REGN has been the subject of a number of other reports. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating for the company in a research note on Thursday, April 30th. Citigroup reissued a “neutral” rating and set a $700.00 price target (down from $900.00) on shares of Regeneron Pharmaceuticals in a report on Monday. Evercore upped their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. Oppenheimer reissued an “outperform” rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Finally, Royal Bank Of Canada dropped their price target on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating for the company in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $810.91.

Regeneron Pharmaceuticals Stock Down 10.9%

REGN stock traded down $75.98 on Monday, reaching $622.27. 1,009,300 shares of the company traded hands, compared to its average volume of 753,718. The firm has a fifty day simple moving average of $744.69 and a 200-day simple moving average of $746.09. The company has a market cap of $65.79 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 1.55 and a beta of 0.30. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm posted $8.22 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals will post 37.1 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. WPG Advisers LLC lifted its stake in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the last quarter. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $26,000. Titan Wealth CI Ltd purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $29,000. Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Regeneron’s phase 3 melanoma trial for fianlimab missed its main goal, weakening confidence in a high-profile pipeline asset and contributing to analyst downgrades. Reuters article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on REGN but cut its price target to $700 from $900, signaling a more cautious valuation view. Tickerreport article
• Neutral Sentiment: Leerink Partners also reaffirmed a market perform rating and lowered its target to $641 from $792, reflecting reduced expectations after the trial setback. Benzinga article
• Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel antibody-Helicon conjugates, a pipeline-expanding deal that could eventually generate significant milestone payments and royalties. Yahoo Finance article

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.